Overview

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

Status:
Completed
Trial end date:
2019-11-05
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HSK7653 tablets in Type 2 Diabetes Mellitus Patients.
Phase:
Phase 2
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.